GM-1489 | 171347-75-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: GM-1489
• 英文别名: N-(2R-2-Carboxymethyl-4-methylpentanoyl)-L-tryptophan (S)-methylbenzyl amide；T2Jbd3H5PG；(3R)-3-[[(2S)-3-(1H-indol-3-yl)-1-oxo-1-[[(1S)-1-phenylethyl]amino]propan-2-yl]carbamoyl]-5-methylhexanoic acid
• CAS: 171347-75-4
• 化学式: C₂₇H₃₃N₃O₄
• 分子量: 463.577
• InChiKey: BLPWNGOQQLJQOL-NRYAXDJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  111
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  GM-1489 以25%的产率得到N-(2R-2-methoxy-carbonylmethyl-4-methylpentanoyl)-L-tryptophan (S)-methylbenzyl amide
  参考文献：
  名称：

  Process for preparing synthetic matrix metalloprotease inhibitors

  摘要：

  揭示了一种合成的哺乳动物基质金属蛋白酶抑制剂，用于治疗或预防由不需要的哺乳动物基质金属蛋白酶活性引起的疾病，包括皮肤疾病、角膜圆锥症、再狭窄、类风湿关节炎、伤口、癌症、血管生成和休克。

  公开号：

  US05892112A1
• 作为产物：
  描述：

  N-(2R-2-methoxy-carbonylmethyl-4-methylpentanoyl)-L-tryptophan (S)-methylbenzyl amide 在 盐酸 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 GM-1489
  参考文献：
  名称：

  Process for preparing synthetic matrix metalloprotease inhibitors

  摘要：

  揭示了一种合成的哺乳动物基质金属蛋白酶抑制剂，用于治疗或预防由不需要的哺乳动物基质金属蛋白酶活性引起的疾病，包括皮肤疾病、角膜圆锥症、再狭窄、类风湿关节炎、伤口、癌症、血管生成和休克。

  公开号：

  US05892112A1

文献信息

• SUTURES AND ANTI-SCARRING AGENTS
  申请人：Angiotech Pharmaceuticals, Inc.

  公开号：EP1978930A2

  公开（公告）日：2008-10-15
• electrical devices, anti-scarring agents, and therapeutic compositions
  申请人：Hunter William L.

  公开号：US20090280153A1

  公开（公告）日：2009-11-12

  Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
• COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS
  申请人：Watson Richard L.

  公开号：US20100008997A1

  公开（公告）日：2010-01-14

  Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent.
• COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
  申请人：Watson Richard L.

  公开号：US20100004189A1

  公开（公告）日：2010-01-07

  Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and/or synergy with tobramycin for treating bacterial infection, and use and/or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions).
• COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
  申请人：Watson Richard L.

  公开号：US20100015235A1

  公开（公告）日：2010-01-21

  Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.